MAPK1 and primary effusion lymphoma: For example, lytic protein vGPCR can activate ERK-2 and p38 pathways in PEL cells, which results in increased tumor cell elaboration of vIL-6 and VEGF, two growth factors involved in PEL pathogenesis [39].